research EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata
Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
Search
for
Sort by
Research
570-600 / 1000+ results 
research Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis
Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
research Using 5 alpha reductase inhibitors safely: What primary care physicians need to know
5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
research Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report
Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
research A new era for alopecia areata: New treatments and improved knowledge of the condition
Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
research Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
research Efficacy of baricitinib in treatment of coexisting alopecia areata and lichen planopilaris
Baricitinib effectively treated hair loss and inflammation in a patient with alopecia areata and lichen planopilaris.
research Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
research Inhibiting Janus kinases to treat alopecia areata
JAK inhibitors might help treat alopecia areata.
research Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
research Prostaglandin E2 prevents radiotherapy-induced alopecia by attenuating transit amplifying cell apoptosis through promoting G1 arrest
Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.
research A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
research 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research 51895 Interim Analysis of Platelet-Rich Plasma (PRP) Treatment for Endocrine Therapy-Induced Alopecia (EIA) and Permanent Chemotherapy-Induced Alopecia (pCIA) in Breast Cancer Patients: A Randomized Controlled Trial
PRP treatment may help improve hair density and thickness in breast cancer patients with therapy-induced hair loss.
research Alopecia areata
Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
research Baricitinib for alopecia areata
Baricitinib is effective in promoting hair growth in severe alopecia areata.
research Signal Peptide-CUB-EGF-like Domain-Containing Protein 3 (SCUBE3): From Molecule to Therapy
SCUBE3 is a potential target for cancer and alopecia treatment but is challenging to target due to its varied roles.
research Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.
research Protein Kinase C as a Therapeutic Target
Protein Kinase C shows promise for cancer treatment, but more research is needed to develop effective inhibitors.
research 5PSQ-056 Experience with tofacinitib and baricitinib in rheumatoid arthritis
Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.
research Litigation associated with 5-alpha-reductase-inhibitor use: A Canadian legal database review.
Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.
research La voie de la PGI2 pour améliorer la cicatrisation des plaies du pied diabétique
Targeting the PGI2 pathway may help heal diabetic foot ulcers.
research 549 Temporary cell cycle arrest in human scalp hair follicles and their epithelial stem cells by ALRN-6924: A novel strategy to selectively protect p53-wildtype cells against paclitaxel-induced alopecia
ALRN-6924 may prevent hair loss caused by chemotherapy.
research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research Therapeutic Response of Alopecia Areata‐Associated Nail Changes to Baricitinib
Baricitinib may effectively treat nail changes in alopecia areata.
research Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
Gefitinib can cause hair loss without scarring.
research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
research JAK inhibitors and alopecia areata
JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.